Neuronetics (NASDAQ: STIM) is a medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. The company’s technology is an office based non-invasive device providing brief treatments delivered in a daily program over several weeks. It was the first company to have a non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment, and it became an industry leader in many countries around the world. The company’s unique technology and impressive results for the outpatient treatment of severe depression enabled its IPO in 2018. Gil Kliman led InterWest’s investment in the company and served on the board in its early days.